Effectiveness and costs of biologics in veterans with rheumatoid arthritis

American Journal of Pharmacy Benefits

Volumn 7, Issue 6, 2015, Pages 280-289

  Sauer, Brian C ^a   Teng, Chia Chen ^a   He, Tao ^a   Leng, Jianwei ^a   Lu, Chao Chin ^a   Curtis, Jeffrey R ^b   Tang, Derek H ^c   Shah, Neel ^c   Harrison, David J ^c   Cannon, Grant W ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; RITUXIMAB;

ADULT; ALGORITHM; ARTICLE; BODY MASS; COST; DRUG COST; DRUG EFFICACY; FEMALE; GENDER; HEALTH CARE MANAGEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; RHEUMATOID ARTHRITIS; SEROLOGY; SMOKING; VETERAN;

EID: 84957577298     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Helmick CG, Felson DT, Lawrence RC, et al; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part I. Arthritis Rheum. 2008;58(1):15-25.
2. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet. 2009;373(9664):659-672.
3. Rindfleisch JA, Muller D. Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2005;72(6):1037-1047.
4. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-2219.
5. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625-639.
6. Choy EH, Kavanaugh AF, Jones SA. The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol. 2013;9(3):154-163.
7. Orencia (abatacept) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2015. http://packageinserts.bms.com/pi/pi_orencia.pdf. Accessed November 17, 2015.
8. Humira (adalimumab) [prescribing information]. North Chicago, IL: AbbVie Inc; 2015. http://www.rxabbvie.com/pdf/humira.pdf. Accessed November 17, 2015.
9. Cimzia (certolizumab pegol) [prescribing information]. Smyrna, GA: UCB, Inc; 2015. https://www.cimzia.com/assets/pdf/Prescribing_Information.pdf. Accessed November 17, 2015.
10. Enbrel (etanercept) [prescribing information]. Thousand Oaks, CA: lmmunex Corporation; 2015. http://pi.amgen.com/united_states/enbrel/derm/enbrel_pi.pdf. Accessed November 17, 2015.
11. Simponi (golimumab) [prescribing information]. Horsham, PA: Janssen Biotech, Inc; 2015. http://www.simponi.com/shared/product/simponi/prescribinginformation. pdf. Accessed November 17, 2015.
12. Remicade (infliximab) [prescribing information]. Malvern, PA: Janssen Biotech, Inc; 2015. http://www.remicade.com/shared/product/remicade/prescribing-information.pdf. Accessed November 17, 2015.
13. Rituxan (rituximab) [prescribing information]. San Francisco, CA: Genentech, Inc; 2014. http://www.gene.com/download/pdf/rituxan_prescribing.pdf. Accessed November 17, 2015.
14. Actemra (tocilizumab) [prescribing information]. San Francisco, CA: Genentech, Inc; 2014. http://www.gene.com/download/pdf/actemra_prescribing.pdf. Accessed November 17, 2015.
15. Stelara (ustekinumab) [prescribing information]. Horsham, PA: Janssen Biotech, Inc; 2014. http://www.stelarainfo.com/pdf/PrescribingInformation.pdf. Accessed November 17, 2015.
16. Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data. Curr Med Res Opin. 2007;23(8):1749-1759.
17. Ollendorf DA, Klingman D, Hazard E, Ray S. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther. 2009;31(4):825-835.
18. Harrison DJ, Huang X, Globe D. Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis. Am J Health Syst Pharm. 2010;67(15):1281-1287.
19. Carter CT, Changolkar AK, Scott McKenzie R. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients. J Med Econ. 2012;15(2):332-339.
20. Bonafede MM, Gandra SR, Watson C, Princic N, Fox KM. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis. Adv Ther. 2012;29(3):234-248.
21. Schabert VF, Watson C, Gandra SR, Goodman S, Fox KM, Harrison DJ. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States. J Med Econ. 2012;15(2):264-275.
22. Cannon GW, DuVall SL, Haroldsen CL, et al. Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis. J Rheumatol. 2014;41(10):1935-1943.
23. Health benefits. US Department of Veterans Affairs website. http://www.va.gov/healthbenefits/cost/copays.asp. Updated June 5, 2015. Accessed November 17, 2015.
24. Curtis JR, Baddley JW, Yang S, et al. Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis. Arthritis Res Ther. 2011;13(5):R155.
25. Curtis JR, Schabert VF, Yeaw J, et al. Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis. J Med Econ. 2014;17(8):555-566.
26. Curtis JR, Schabert VF, Harrison DJ, et al. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims. Clin Ther. 2014;36(7):996-1004.
27. Nelson SD, Lu CC, Teng CC, et al. The use of natural language processing of infusion notes to identify outpatient infusions. Pharmacoepidemiol Drug Saf. 2015;24(1):86-92.
28. Leng J, Lu CC, Cannon GW, Teng C-C, Zhou X, He T. Performance of NLP tool designed to identify and extract biologic drug infusion data from clinical notes. Value Health. 2014;17(3):A187.
29. Hamilton RJ. Tarascon Pharmacopoeia 2011 Library Edition. Philadelphia, PA: Tarascon; 2011.
30. Pharmacy Benefits Management Services: pharmaceutical prices. US Department of Veterans Affairs website. http://www.pbm.va.gov/PharmaceuticalPrices.asp. Updated June 3, 2015. Accessed November 17, 2015.
31. Poole C. Beyond the confidence interval. Am J Public Health. 1987;77(2):195-199.
32. Poole C. Low P-values or narrow confidence intervals: which are more durable? Epidemiology. 2001;12(3):291-294.
33. Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Curr Med Res Opin. 2008;24(8):2229-2240.
34. Moots RJ, Haraoui B, Matucci-Cerinic M, et al. Differences in biologic doseescalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Clin Exp Rheumatol. 2011;29(1):26-34.
35. Etemad L, Yu EB, Wanke LA. Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis. Manag Care Interface. 2005;18(4):21-27.
36. Bonafede MM, Gandra SR, Fox KM, Wilson KL. Tumor necrosis factor blocker dose escalation among biologic naive rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation. J Med Econ. 2012;15(4):635-643.
37. Schabert VF, Bruce B, Ferrufino CF, et al. Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study. Curr Med Res Opin. 2012;28(4):569-580.
38. Ogale S, Hitraya E, Henk HJ. Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord. 2011;12:204.
39. Krieckaert CL, Jamnitski A, Nurmohamed MT, Kostense PJ, Boers M, Wolbink G. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum. 2012;64(12):3850-3855.
40. Pascual-Salcedo D, Plasencia C, Ramiro S, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford). 2011;50(8):1445-1452.
41. Dore RK, Mathews S, Schechtman J, et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2007;25(1):40-46.
42. Weinblatt ME, Genovese MC, Schiff MH, et al. Immunogenicity is low and transient with intravenous (IV) abatacept therapy: results from a large pooled analysis of 3985 patients (pts) with rheumatoid arthritis (RA) and up to 8 years’ exposure [abstract]. Arthritis Rheum. 2011;63(suppl 10):S854.
43. Ahlmén M, Svensson B, Albertsson K, Forslind K, Hafström I; BARFOT Study Group. Influence of gender on assessments of disease activity and function in early rheumatoid arthritis in relation to radiographic joint damage. Ann Rheum Dis. 2010;69(1):230-233.
44. Forslind K, Hafström I, Ahlmén M, Svensson B; BARFOT Study Group. Sex: a major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis. 2007;66(1):46-52.
45. Sokka T, Toloza S, Cutolo M, et al; QUEST-RA Group. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther. 2009;11(1):R7.
46. Tengstrand B, Ahlmén M, Hafström I. The influence of sex on rheumatoid arthritis: a prospective study of onset and outcome after 2 years. J Rheumatol. 2004;31(2):214-222.
47. Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, et al; GISEA Group. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol. 2007;34(8):1670-1673.
48. Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2006;45(12):1558-1565.
49. Yamanaka H, Tanaka Y, Sekiguchi N, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol. 2007;17(1):28-32.
50. Kvien TK, Uhlig T, Ødegård S, Heiberg MS. Epidemiological aspects of rheumatoid arthritis: the sex ratio. Ann N Y Acad Sci. 2006;1069:212-222.
51. Jawaheer D, Messing S, Reed G, et al. Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of North America cohort of rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2012;64(12):1811-1818.